An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Eligible patients, for whom the treating physician has decided to initiate treatment with Tarceva according to the local label will be followed for 18 months.
Non-Squamous Non-Small Cell Lung Cancer
Progression-free survival rate at 18 months, 3.5 years
Response rate (complete response/partial response) by type of mutation, 3.5 years|Percentage of patients with remission, 3.5 years|Progression-free survival (overall/stratified), 3.5 years|Overall survival (overall/stratified), 3.5 years|Tolerability: Incidence of fatigue, rash, diarrhea, 3.5 years|Safety: Incidence of serious adverse events, 3.5 years|Dose modifications/withdrawals, 3.5 years|Symptom control (cough, dyspnea), 3.5 years
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Eligible patients, for whom the treating physician has decided to initiate treatment with Tarceva according to the local label will be followed for 18 months.